CVA Family Office’s Moleculin Biotech MBRX Stock Holding History

CVA Family Office’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3	Hold	1	–	–	﹤0.01%	1802
2026 Q1	$2	Hold	1	–	–	﹤0.01%	1838
2025 Q4	$3	Hold	1	–	–	﹤0.01%	1288
2025 Q3	$18	Hold	1	–	–	﹤0.01%	1297
2025 Q2	$10	Hold	1	–	–	﹤0.01%	1279
2025 Q1	$33	Hold	1	–	–	﹤0.01%	1385
2024 Q4	$58	Hold	1	–	–	﹤0.01%	1281
2024 Q3	$97	Hold	1	–	–	﹤0.01%	1259
2024 Q2	$120	Hold	1	–	–	﹤0.01%	1264
2024 Q1	$201	Hold	1	–	–	﹤0.01%	1044
2023 Q4	$429	Buy	+1	New	+$208	﹤0.01%	1020
2023 Q3	–	Sell	-1	Closed	-$289	–	658
2023 Q2	$289	Hold	1	–	–	﹤0.01%	995
2023 Q1	$480	Hold	1	–	–	﹤0.01%	942
2022 Q4	$530	Hold	1	–	–	﹤0.01%	896
2022 Q3	$1K	Hold	1	–	–	﹤0.01%	852
2022 Q2	$1K	Hold	1	–	–	﹤0.01%	875
2022 Q1	$1K	Hold	1	–	–	﹤0.01%	927
2021 Q4	$1K	Buy	+1	New	+$887	﹤0.01%	880
2021 Q3	–	Sell	-1	Closed	-$2K	–	658
2021 Q2	$2K	Hold	1	–	–	﹤0.01%	888
2021 Q1	$2K	Buy	+1	New	+$1.83K	﹤0.01%	709

Other funds holding MBRX

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CVA Family Office's MBRX Position: Q2 2026 in Review

CVA Family Office held its Moleculin Biotech (MBRX) position steady in Q2 2026 at 1 share worth $3. The position accounts for ﹤0.01% of the portfolio, ranked #1802.

CVA Family Office first reported a position in MBRX in Q1 2021 and has held it in 20 quarters since. The position peaked at $2K in Q2 2021. 18 funds tracked by Wall St. Rank hold MBRX as of Q2 2026.

CVA Family Office held 1 share of Moleculin Biotech worth $3 as of Q2 2026.
CVA Family Office left its Moleculin Biotech share count unchanged in Q2 2026.
Moleculin Biotech made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1802 holding.
CVA Family Office first reported a position in Moleculin Biotech in Q1 2021 and has held it in 20 quarters since.
CVA Family Office's Moleculin Biotech position peaked at $2K in Q2 2021.
18 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.